[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355722-105":59,"doc-detail-355722-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","cancer-signaling-networks-in-tumor-progression-and-drug-resistance-crosstalk-adaptive-reprogramming-and-therapeutic-targeting","Cancer signaling networks in tumor progression and drug resistance: Crosstalk, adaptive reprogramming and therapeutic targeting","","Cancer signaling networks are highly dynamic, interconnected systems that orchestrate tumor initiation, progression, therapeutic response and drug resistance. Rather than acting as isolated routes, they integrate extracellular and intracellular cues through coordinated interactions among membrane receptors, intracellular transducers and downstream effectors. Evidence highlights pathway crosstalk, feedback control and adaptive reprogramming as drivers of phenotypic plasticity, microenvironmental adaptation and resistance. This review summarizes core network architecture and major oncogenic pathways, emphasizing PI3K/Akt/mTOR, MAPK/ERK and Wnt/β-catenin signaling, and explains why single-pathway blockade yields limited, transient benefit. Network-level insights guide rational multi-target targeting strategies.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cancer-signaling-networks-in-tumor-progression-and-drug-resistance-crosstalk-adaptive-reprogramming-and-therapeutic-targeting/355722/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cancer-signaling-networks-in-tumor-progression-and-drug-resistance-crosstalk-adaptive-reprogramming-and-therapeutic-targeting/355722.png","ImageObject",300,407,{"name":92,"@type":93},"Đào","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What roles do cancer signaling networks play in tumor development and therapy?","Question",{"text":113,"@type":114},"They regulate tumor initiation, progression, therapeutic response and drug resistance. Their coordinated signaling also shapes malignant behaviors such as proliferation, apoptosis, invasion and immune evasion.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Why does pathway crosstalk and feedback reduce the effectiveness of single-pathway inhibition?",{"text":118,"@type":114},"Network-level interactions enable compensatory activation and context-dependent outputs. These dynamic properties can restore signaling through bypass routes, limiting clinical benefit.",{"name":120,"@type":111,"acceptedAnswer":121},"Which signaling pathways are emphasized in this review?",{"text":122,"@type":114},"The review focuses on PI3K/Akt/mTOR, MAPK/ERK and Wnt/β-catenin signaling. It discusses how these pathways embed within the broader cancer signaling network architecture.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},355722,1790144325,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":41,"preview_page_count":14,"preview_urls":146},1374402968488,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","ONCOLOGY REPORTS 56: 126, 2026  \nCancer signaling networks in tumor progression and drug resistance: Crosstalk, adaptive reprogramming and therapeutic targeting (Review)  \nHONGYAN LI 1* , SHIYUAN SONG2* , LINLIN WANG2 and QIANG LIU 1  \n1Oncology Department of Integrated Traditional Chinese and Western Medicine, Shenyang Tenth People's Hospital, Shenyang, 2  \nLiaoning 110044, P.R. China; Department of Thoracic Surgery, Shenyang Tenth People's Hospital, Shenyang, Liaoning 110044, P.R. China  \nReceived September 17, 2025; Accepted April 28, 2026  \nDOI: 10. 3892/or.2026.9131  \nAbstract. Cancer signaling networks, highly dynamic with interconnected systems, regulate tumor initiation, its progres‑ sion, therapeutic response and drug resistance. Rather than functioning as isolated pathways, these networks integrate extracellular and intracellular signals through coordinated interactions among membrane receptors, intracellular trans‑ ducers and downstream effectors . Increasing evidence suggests that pathway crosstalk, feedback regulation and adap‑ tive reprogramming are central to tumor phenotypic plasticity, microenvironmental adaptation and resistance to therapy. In this review, the core architecture of cancer signaling networksand the major oncogenic pathways embedded within them were summarized with a particular focus on PI3K/Akt/mTOR, MAPK/ERK and Wnt/β‑catenin signaling. The dynamic network properties that shape cancer behavior, including compensatory activation, context‑dependent signaling outputs and interactions with the tumor microenvironment, were further discussed. These features provide insights into why single‑pathway inhibition often produces only a limited and transient clinical benefit. Importantly, a network‑level understanding of cancer signaling has major translational implications. Therapeutic resistance frequently arises through pathway reactivation, bypass signaling and adaptive repro‑ gramming, necessitating rational combination strategies  \nCorrespondence to: Dr Linlin Wang, Department of Thoracic Surgery, Shenyang Tenth People's Hospital, 11 Beihai Street, Dadong, Shenyang, Liaoning 110044, P.R. China  \nE‑mail: [lsywll@126.com](lsywll@126.com)  \nDr Qiang Liu, Oncology Department of Integrated Traditional Chinese and Western Medicine, Shenyang Tenth People's Hospital, 11, Beihai Street, Dadong, Shenyang, Liaoning 110044, P.R. China  \nE‑mail: [liuqiang8866@126.com](liuqiang8866@126.com)  \n*Contributed equally  \nKey words: cancer signaling networks, drug resistance, pathway crosstalk, adaptive reprogramming, precision oncology  \nand multi‑target interventions . Advances in multi‑omics, single‑cell and spatial technologies and computational modeling are crucial for characterizing signaling network dynamics and identifying clinically relevant vulnerabilities.  \nContents  \n1. Introduction  \n2. Core architecture of cancer signaling networks  \n3. Core oncogenic signaling pathways  \n4. Dynamic network properties: Crosstalk, feedback and adaptive reprogramming  \n5. Signaling networks, tumor phenotypes and therapeutic implications  \n6. Current challenges and future perspectives  \n7. Conclusion  \n1. Introduction  \nCancer cell signaling networks are highly complex and dynamically regulated systems that play key roles in tumor initiation, its progression, metastasis, therapeutic response and drug resistance (1) . Rather than functioning as isolated pathways, these networks operate through extensive crosstalk and feedback among multiple signaling cascades, thereby regulating key malignant behaviors such as proliferation, apoptosis, invasion, metabolic reprogramming and immune evasion (2) . Advances in multi‑omics and systems biology have offered deeper insights into the organization and regu‑ latory principles of these networks (3,4) . Such insights have improved the current understanding of tumor heterogeneity and evolutionary dynamics, while also identifying new therapeutic targets and more individualized treatment strat","cbCaiteAB9bkWib5","https://ap.wps.com/l/cbCaiteAB9bkWib5","pdf",3357977,12,"English","# 1. Introduction\n# 2. Core architecture of cancer signaling networks\n# 3. Core oncogenic signaling pathways\n# 4. Dynamic network properties: Crosstalk, feedback and adaptive reprogramming\n# 5. Signaling networks, tumor phenotypes and therapeutic implications\n# 6. Current challenges and future perspectives\n# 7. Conclusion","[{\"question\":\"What roles do cancer signaling networks play in tumor development and therapy?\",\"answer\":\"They regulate tumor initiation, progression, therapeutic response and drug resistance. Their coordinated signaling also shapes malignant behaviors such as proliferation, apoptosis, invasion and immune evasion.\"},{\"question\":\"Why does pathway crosstalk and feedback reduce the effectiveness of single-pathway inhibition?\",\"answer\":\"Network-level interactions enable compensatory activation and context-dependent outputs. These dynamic properties can restore signaling through bypass routes, limiting clinical benefit.\"},{\"question\":\"Which signaling pathways are emphasized in this review?\",\"answer\":\"The review focuses on PI3K/Akt/mTOR, MAPK/ERK and Wnt/β-catenin signaling. It discusses how these pathways embed within the broader cancer signaling network architecture.\"}]","Cancer signaling networks in tumor progression and drug resistance: Crosstalk, adaptive reprogramming and therapeutic targeting | PDF",1790120640,[147,151],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/d205073f73cbe9295243794c3fdf1ec1.webp",983,1357,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/5bf5f25b328900541cc71623d57c3649.webp",982,1356]